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Liposarcoma is a malignancy that was first described by 
Rudolf Virchow in 1857 in a patient with a tumor of the 
thigh (1). Soft tissue sarcomas include many subtypes, 
including liposarcomas, and are anticipated to have an 
incidence of 13,040 in the US in 2018 (2). Liposarcomas are 
uncommon comprising roughly 17% of soft tissue sarcomas. 
Peak incidence is between 40 and 60 years old, and there is a 
slight male predominance. More than 50% of liposarcomas 
occur in the thigh as painless, indolent masses (3). Roughly 
1/3 of liposarcomas arise from the retroperitoneum 
where they can grow to massive size due to few clinical 
signs and their slow growth rate (4). Stout, in 1944, 
classified the liposarcomas into histologic subgroups (5). 
The gross appearance of liposarcomas range from the 
myxoid liposarcomas (MLPS)—“slimy greyish white 
tumours bearing some resemblance to a true myxoma” to 
“yellow masses which may contain firmer areas of paler 
colour”. An early (1970) case series of 60 patients with 
liposarcoma revealed a 10% occurrence of pyrexia that 
remitted with resection of the tumors. Of these 6 patients, 4 
had pleomorphic tumors, 1 lipoma like and 1 was myxoid. 5 
of the 6 febrile patients died of their disease (6). Fevers are 
no longer considered a hallmark of liposarcomas. 
Overall survival
Determining the overall survival of patients with soft tissue 
sarcomas can be challenging due to the complexity of the 
disease, the range of modalities used to treat it and hence, 
the distributed nature of records. A 2018 high quality 
retrospective review lends important data to our knowledge 
base. A total of 130 physicians, with experience treating soft 
tissue sarcomas, across Europe were recruited to abstract 
data from medical records. Charts of 805 patients from the 
United Kingdom, Spain, Germany and France, who were 
diagnosed with soft tissue sarcomas for which no surgical 
or radiation options remained, were reviewed. Patients with 
liposarcoma (n=105) received first line chemotherapy with 
doxorubicin alone (61.8%), doxorubicin and ifosfamide 
(14.3%), docetaxel and gemcitabine (2.9%), docetaxel alone 
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(2.9%) and trabectedin (2.9%). Responses were deemed 
complete response (CR) (3.8%), partial response (PR) 
(32.4%), stable disease (30.5%) and progressive disease 
(30.5%). The median overall survival was 16.3 months [95% 
confidence interval (CI): 13.3–21.0] (7). Whether or not 
chemotherapy impacts overall survival in patients with soft 
tissue sarcoma remains an open question. A 2018 publication 
reported on 150 patients with high risk, resected soft tissue 
sarcomas. High risk was defined as high grade (2 or 3), large 
size (≥8 cm), vascular invasion or infiltrative growth and 
invasion pattern. All patients were treated with 6 cycles of 
adjuvant doxorubicin and ifosfamide, with radiation between 
cycles 3 and 4. The 5-year overall survival was 76.1% which 
compared favorably with historical controls which had a 
50% 5-year overall survival rate with adjuvant radiation 
alone (8). This trial is suggestive, but not conclusive, for the 
survival benefit of adjuvant chemotherapy. A retrospective 
analysis of 16,370 patients with stage III soft tissue sarcoma 
treated between 1998 and 2012 in the United States was 
performed on the National Cancer Data Base (NCDB). 
There was a statistically significant (P<0.001) superior 
overall survival for those receiving chemotherapy, compared 
with those who did not receive chemotherapy (82.7 versus 
51.3 months). The benefit was most pronounced in 
pleiomorphic undifferentiated sarcoma patients (9).
Histologic subtypes
Histologic subtypes of liposarcoma have been described, 
but there has been variability in the terms used. We now 
commonly describe four subtypes—well differentiated 
liposarcoma (WDLPS), dedifferentiated liposarcoma 
(DDLPS) ,  MLPS and  p leomorphic  l iposarcoma 
(PLPS). Generally, the myxoid and well differentiated 
behave as low-grade tumors, with the pleomorphic and 
dedifferentiated demonstrating more aggressive, high-
grade behaviors. Memorial Sloan Kettering Cancer Center 
has reported the largest series. This was a retrospective 
review of prospectively collected data for all patients with 
liposarcoma treated at their institution between 1982 and 
2005. They observed a predilection of myxoid, round 
cell and pleomorphic tumors for the extremities, and 
well-differentiated and dedifferentiated subtypes for the 
retroperitoneum. Overall, 910 patients underwent resection 
during that period, and 801 were evaluable. None of the 
patients had metastases at the time of presentation. The 
subtypes seen included 46.2% WDLPS, 17.9% DDLPS, 
18.0% MLPS, 10.0% round cell and 8.0% PLPS. Of these 
tumors, 56.5% were extremity primaries, and 33.5% were 
retroperitoneal. Overall, survival data varied by tumor 
subtype with 5-year disease specific (93% WDLPS, 44% 
DLPS, 92% MLPS, 74% round cell and 59% PLPS) and 
12-year disease specific survival (78% WDLPS, 38% DLPS, 
86% MLPS, 55% round cell and 53% PLPS) rates. These 
data have been used to construct prognostic nomograms for 
not only histologic subtype, but also primary location, and 
margin status (10) (Figure 1).
Molecular changes
MLPS usually carries a translocation of t(12;16)(q13;p11) 
involving the DDIT3 and FUS genes (11). A fusion of 
EWSR1-DDIT3 has been described less commonly. 
MLPS tumors often express high levels of NY-ESO-1, an 
immunogenic cancer testis antigen that is a potential target 
for vaccine-based therapies (12). WDLPS and DDLPS 
comprise roughly 65% of liposarcomas. Clinically, they can 
demonstrate late recurrences following surgical resection. 
The use of molecular diagnostic techniques is better 
characterizing these groups. 
There is a high prevalence of amplification of the 12q14-
15 region in WDLPS and DDLPS tumors (Figure 2). 
This contains the p53 and CDK4 genes which may 
translate to therapeutic differences with the use of drugs 
such as palbociclib and abemaciclib. Similarly, MDM2 
targeting agents are now in development. RG7112 is a 
drug developed to inhibit MDM2 (14). Other targets under 
study in the WDLPS/DDLPS subtype include CRM1—the 
chromosome region maintenance 1 protein, insulin growth 
factor-1, MET and PDGFRB. 
Location
Patterns of recurrence in retroperitoneal sarcomas vary by 
subtype. In a review of 675 patients with retroperitoneal 
sarcomas that underwent surgical exploration at Memorial 
Sloan Kettering Cancer from July 1982 to July 2010, 
liposarcomas were separated into a high-grade group 
(DDLPS, round cell and PLPS) and a low-grade group 
(WDLPS and MLPS). Totally, 85% of patients were able to 
have a total gross excision, 9% had grossly positive margins 
and 6% underwent an exploratory laparotomy but not a 
resection. The disease specific death (DSD) rate was 25% 
at 10 years for the low risk group, and 53% for the high-
risk group. The high-grade liposarcoma local recurrence 
rate was 58% by 5 years and 62% at 15 years demonstrating 
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a preponderance of early, local recurrences. In contrast, 
the low-grade liposarcomas had a 35% local recurrence 
rate at 5 years with a 60% cumulative rate at 15 years. 
Distant metastatic disease was present at 10 years in 58% 
of high-grade liposarcoma patients and 15% in low grade 
liposarcoma patients (15). 
A historical view of chemotherapy for 
liposarcoma
A report of 88 patients with liposarcomas who received 
chemotherapy between September 1979 and June 2004 who 
were treated at the Royal Marsden Hospital were reviewed 
retrospectively, though the data was captured prospectively. 
Patients analyzed had received chemotherapy for recurrent 
or metastatic disease, not in the adjuvant setting. In this 
evaluation, there were 27 myxoid, 13 round cell, 16 well-
differentiated, 16 dedifferentiated, 15 pleomorphic and 
1 unspecified liposarcoma. MLPSs demonstrated the 
highest response rate with 48% achieving a PR to first 
line chemotherapy compared with 18% of non-MLPSs. 
The response rate for combined well-differentiated and 
DDLPSs was only 11%. The number of patients was too 
small to analyze the response rate to different chemotherapy 
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Figure 1 Nomogram for predicting 5- and 12-year liposarcoma-specific survival probabilities. DSS, disease-specific survival.
Table 3 p53 and MDM2 immunreactivity with histopathologic typing
Tumor type (%) Number of patients (%) p53 positive (%) MDM2 positive (%) p53/MDM2 positive (%)
WDL 20 7 (35) 6 (30) 3 (15)
ML 16 8 (50) 8 (50) 6 (37.5)
PL 7 2 (28.6) 3 (42.9) 2 (28.6)
DL 5 5 (100) 5 (100) 5 (100)
Total 48 22 (45.8) 22 (45.8) 16 (33.3)
WL, well differentiated liposarcoma; ML, myxoid liposarcoma; PL, pleomorphic liposarcoma; DL, defferentiated liposarcoma.
Figure 2 High prevalence of amplification of the 12q14-15 region in WDLPS and DDLPS tumors (13). WDLPS, differentiated 
liposarcoma; DDLPS, dedifferentiated liposarcoma.
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regimens by histologic subtype. Of the myxoid patients, 5 of 
7 patients treated with Doxorubicin responded as died 7 of 
the 12 patients treated with doxorubicin and ifosfamide (16). 
The value of adjuvant or neoadjuvant therapy for 
sarcoma is tied not only to histologic subtype, but also to 
location. Retroperitoneal sarcomas are usually identified at 
large size. In a 1981 trial, Doxorubicin was administered 
neoadjuvantly to 10 patients (intra-arterially in 2 and 
intravenously in 8) at UCLA. Four patients also received 
radiation. Three patients had significant shrinkage pre-
operatively, though the authors did not provide details of 
which therapies the responders underwent, or the doses of 
either chemotherapy or radiation that were delivered. This 
added to the conversation around adjuvant and neoadjuvant 
therapy but did not distinguish among sarcoma types (17).
Unlike many other solid tumors, sarcoma is not generally 
acknowledged to be highly responsive to chemotherapy. 
A 1972 report in the Proceedings of the National Cancer 
Conference reviewed 91 patients treated at Henry Ford 
Hospital between January 1963 and July 1972 who had 
metastatic soft tissue sarcomas deemed “impossible to 
treat” by surgery or radiation. This included 7 patients with 
liposarcoma. Four of which were retroperitoneal. There 
was 1 PR in this group—a 14-year-old girl responded to 
cyclophosphamide and vincristine, and a 52-year-old man had 
stable disease for over a year to actinomycin D. Histologic 
subtypes of these tumors were not reported (18). In 1973, 
an editorial in the journal Surgery, Gynecology and Obstetrics 
stated “None of the currently used chemotherapeutic agents, 
to my knowledge, is effective in the management of primary 
soft tissue sarcomas in adults.” (19). 
Doxorubicin, ifosfamide, gemcitabine, docetaxel, 
trabectedin and eribulin are now considered to be some 
of the most active agents in the treatment of soft tissue 
sarcomas in general, and liposarcoma in specific. The 
limitation of available data related to the subtypes’ 
responsiveness to different agents is reflected in the absence 
of such discussions in review articles about these agents. 
A 2015 systematic review of gemcitabine-based regimens 
in sarcoma did not reference the histologic subtypes of 
liposarcoma (20). 
Anthracyclines are some of the first drugs to demonstrate 
meaningful efficacy in soft tissue sarcoma. In a 1972 report 
from the Southwest Cancer Chemotherapy Study Group, 
Daunomycin was used in progressive metastatic soft tissue 
sarcomas in children, and objective tumor shrinkage was 
seen in 4/21 treated patients. Only one of the patients had 
a liposarcoma—described as a lipomyxosarcoma—and that 
patient did not respond (21). A review of 2,185 patients 
with advanced (relapsed, unresectable or metastatic) soft 
tissue sarcoma who were treated on 7 studies conducted 
by the Soft Tissue and Bone Sarcoma Group (STBSG) of 
the European Organization for Research and Treatment 
of Cancer (EORTC) were reviewed. These trials included 
doxorubicin and epirubicin based regimens. Overall survival 
times were indistinguishable across the regimens, and 
the overall response rate was 26% with considerable, but 
statistically insignificant, variation across treatment arms. 
In this analysis, liposarcoma patients had a statistically 
significantly superior median overall survival (76 vs. 
51 weeks, P=0.0005) (22).
Do different subtypes of liposarcoma respond 
differently to chemotherapy? 
There is good evidence that histologic subtypes of sarcoma 
respond differently to distinct regimens of chemotherapy (23). 
A case report in 1983 described the dramatic response 
of a patient with a poorly differentiated MLPS of 
the retroperitoneum to treatment with prednisolone, 
cyclophosphamide, vincristine and actinomycin D (24). In 
1994 a study of sensitivity of subtypes of sarcomas using 
the succinate dehydrogenase inhibition (SDI) test was 
reported. This chemosensitivity assay was based on the 
reduction in succinate dehydrogenase activity (SDI) in 
drug exposed cells to less than 50% of that in control cells. 
This reduction serves as a surrogate marker of cell death. 
This assay demonstrated sensitivity of leiomyosarcoma 
for doxorubicin, and for liposarcoma to cisplatin and 
aclacinomycin A (an early anthracycline) (25). 
The combination of Gemcitabine and Docetaxel is 
effective in leiomyosarcoma but not in MLPS. A phase 
II trial of this combination in 44 eligible patients with 
leiomyosarcoma demonstrated a 25% PR and 36.6% stable 
disease rate (26). In contrast, doxorubicin combined with 
ifosfamide demonstrated a 43.2% overall response rate in a 
retrospective study of 27 patients with MLPS (27). 
MD Anderson reported on 44 patients with MLPS 
presented at the multidisciplinary planning conference 
between 1986 and 1992. A total of 21 of these patients 
received systemic chemotherapy, 20 were evaluable and 
of these, 18 received doxorubicin as a continuous infusion 
with dacarbazine with or without cyclophosphamide. There 
were 8 objective responses (1 complete) for a response 
rate of 44% (28). A subsequent report from MD Anderson 
described 37 chemotherapy naive patients with MLPS 
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who were treated between 1/00 and 12/09. These patients 
received up to 8 cycles of doxorubicin and ifosfamide. The 
response rate of 43% was the same for locally advanced and 
metastatic disease (27). 
Studies of newer agents give greater insight into 
differential response rates due to more stringent attention 
to tissue subtypes. Trabectedin gained Food and Drug 
Administration (FDA) approval for leiomyosarcomas and 
liposarcomas in 2015. Expanded access to trabectedin was 
evaluated for 1,895 patients. Only 807 were assessable. 
Clinical benefit [CR, PR or stable disease] was seen in 
54% of the 258 patients with either leiomyosarcoma or 
liposarcoma, compared with 38% of patients with other 
soft tissue sarcomas (29,30). The MLPSs appears to be 
particularly sensitive to trabectedin. The mechanism 
has been proposed to be functional inactivation of the 
oncogenic chimera FUS-CHOP, with a downstream 
impact on adipocyte differentiation. The authors studying 
this mechanism commented that “To our knowledge this 
is the first report indicating that a small molecule can 
displace an oncogenic transcription factor in vivo from its 
target DNA sequences, thus specifically modulating the 
transcription of genes involved in the pathogenesis of a 
neoplastic disease.” (31).
Aldoxorubicin is an albumin bound doxorubicin prodrug 
that was compared with doxorubicin in a phase II trial 
of patients with advanced soft tissue sarcomas. Despite 
improvement in median progression free survival (PFS) 
(5.6 vs. 2.7 months, P=0.02) and response rate (25% vs. 
0%), there was no improvement in median overall survival 
(15.8 vs. 14.3 months) (32). A subsequent phase III clinical 
trial compared aldoxorubicin with physician’s choice 
chemotherapy. There were no differences in overall survival 
for the group as a whole, but the liposarcoma subset had 
prolonged median PFS (5.3 vs. 3.0 months, P=0.007). There 
was no commentary on specific liposarcoma subtypes (33).
Olaratumab (a human anti-PDGFR alpha monoclonal 
antibody) was studied in a randomized trial as a combination 
therapy with doxorubicin versus doxorubicin alone in 
patients with anthracycline naive advanced soft tissue 
sarcoma. In this phase Ib/II study, median survival was 
12 months longer in the combined therapy arm (26.5 vs. 
14.7 months, P=0.0003). Interestingly, objective response 
rate and PFS did not differ between the two groups. No 
characterization of liposarcoma subtypes was made (34). 
The results of a phase III trial as first line treatment has 
completed accrual but results have not yet been published. 
When considering the variability of sarcomas response 
to therapy, it is important to consider why this might be. 
The data from anti-angiogenesis agents gives an important 
clue. There is a difference in the level of platelet-derived 
growth factor receptors (PDGFRA and PDGFRB), and 
vascular endothelial growth factor receptors (VEGFR-1 
to VEGFR-3) in different subtypes of soft tissue sarcoma. 
Pazopanib and sunitinib are tyrosine kinase inhibitors that 
act on these targets, and histologic subtypes of sarcomas 
have a broad range of response rates (35). Early studies 
of pazopanib demonstrated a clinically and statistically 
significant decreased efficacy in the liposarcoma subset 
of soft tissue sarcomas. For that reason, liposarcomas are 
routinely excluded from further trials of pazopanib (36).
Regorafenib is an oral tyrosine kinase inhibitor that 
binds to and inhibits VEGFRs 2 and 3, as well as, Ret, 
Kit, PDGFR and Raf. This agent was studied in a phase 
II, randomized trial compared with placebo in four soft 
tissue sarcoma subtypes (liposarcoma, leiomyosarcoma, 
synovial sarcoma and mixed histologies). PFS was superior 
in all subgroups except liposarcoma, and overall survival 
was superior in the pooled subgroups when liposarcoma 
was excluded. In the liposarcoma subgroup analysis, PFS 
was 1.1 month in the regorafenib group compared with 
1.7 months with placebo (37).
WDLPS and DDLPS have amplification of CDK4 in 
90% of cases. A clinical trial of 60 WDLPS or DDLPS 
patients treated with palbociclib, an oral CDK4 and 
CDK6 inhibitor, at the doses approved by the FDA for the 
treatment of patients with breast cancer—125 mg daily 
for 21 out of 28 days. The study used PFS as its primary 
endpoint, and at 12 weeks (PFS12) the rate was 57.2%. 
There was one CR observed (38).
The original phase II trial of pazopanib in soft tissue 
sarcomas revealed minimal activity in liposarcomas. The 
study used progression free rate (PFR) as its primary 
endpoint, and at 12 weeks (PFR12), this was demonstrated 
in only 5/19 (26%) of liposarcoma patients compared with 
18/41 (44%) of leiomyosarcoma patients, 18/38 (49%) 
of synovial sarcoma patients and 16/41 (39%) of patients 
with other soft tissue subtypes (36). On the basis of this 
difference, patients with liposarcoma have been excluded 
from subsequent trials of pazopanib. This was revisited 
in 2017 with the publication of a single arm, phase II 
trial of pazopanib in advanced liposarcoma patients that 
demonstrated a PFR12 of 68.3%. More interestingly, at 
24 weeks, 39% of patients were progression free and the 
median overall survival was 12.6 months. In this study, the 
PFR12 was 74.1% for DDLPS, and 66.7% for myxoid/
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round cell liposarcoma. The number of patients with PLPSs 
was felt to be too small to be assessable (39).
In a proof of concept study, 20 patients were enrolled 
at 4 centers in France and treated with the novel agent 
RG7112. Totally, 14 of 17 assessable patients with WDLPS 
or DDLPS expressed amplification of the MDM2 gene, 
the target of this agent. After a maximum of 4 28-day 
cycles of this therapy in the neoadjuvant context, 1 PR and 
14 stable diseases were observed. Toxicity was significant 
and predominantly hematologic (13).
The, as yet, limited data on the role of immune checkpoint 
inhibitors in soft tissue sarcomas overall precludes any 
comparison among the subtypes of liposarcoma. A single 
arm trial, SARC28, enrolled a cohort of 10 patients with 
DDLPS to treatment with Pembrolizumab. Two PRs were 
observed. Of note, there were 6 patients with soft tissue 
sarcoma in the overall trial that responded, but only 2 were 
positive for programmed death ligand 1 (PD-L1) (40). 
Additional trials are underway exploring combination anti-
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
and programmed death-1 (PD-1) inhibitors, as well as, the 
integration of chemo and immunotherapies. It is premature 
to surmise significant efficacy in soft tissue sarcomas as a 
whole, and insufficient data exists to allow any suppositions 
about response rates across the subtypes. 
Adjuvant therapy
There is limited reported, detailed information about the 
response of subtypes of liposarcoma to adjuvant therapy. 
Zagars et al. reported a <10% local recurrence rate with 
almost no metastatic disease in patients with WDLPSs 
treated with radiation following resection, compared with 
roughly 33% local recurrence and 40% metastases for 
similarly treated PLPSs (41). 
There have been several major studies exploring adjuvant 
chemotherapy. The Italian Sarcoma Group compared 
3 versus 5 cycles of adjuvant epirubicin and ifosfamide in 
patients with high risk spindle cell sarcoma of the superficial 
trunk or limbs who had undergone resection ± radiation. 
This study was stopped early (at a median 59 month follow 
up) when there was a significant positive improvement 
in both disease free and overall survival (42). At a later 
follow up assessment (median 90 month follow up), the 
improvement due to adjuvant chemotherapy versus no 
treatment lost statistical significance (43).
Adjuvant chemotherapy for soft tissue sarcoma was 
evaluated in a randomized study of doxorubicin and 
ifosfamide versus no therapy in EORTC 62931. This, the 
largest such trial, in 351 patients with macroscopically 
resected soft tissue sarcoma, demonstrated no benefit from 
chemotherapy in terms of local control, relapse free or 
overall survival (44,45).
Neoadjuvant therapy (treatment prior to surgery) carries 
the theoretical benefit of treating occult metastases early 
in the course of therapy, or reducing the extent of required 
resection. The potential downside to this approach includes 
impaired wound healing and the possibility that a resectable 
tumor might grow through ineffective treatment and 
become unresectable. In patients with surgically resected 
soft tissue sarcomas, the complication rate for preoperative 
radiation was 22% compared with 6% for post-operative 
radiation (46). 
The role of adjuvant chemotherapy was studied in a phase 
three Italian Sarcoma Group trial in patients with high 
risk superficial trunk or limb soft tissue sarcoma. Patients 
received 3 neoadjuvant cycles of epirubicin and ifosfamide 
and either no additional chemotherapy or 2 cycles in the 
adjuvant setting. Radiation could be given either pre or post 
operatively. There was no significant difference in 10-year 
overall survival between the groups (47).
As the importance of histologic subtypes has been 
increasingly recognized, we are exploring how to incorporate 
it into treatment decisions. A phase 3 randomized trial 
of neoadjuvant treatment in patients with high risk, yet 
resectable, soft tissue sarcoma of the trunk wall or limb, 
compared 3 cycles of epirubicin and ifosfamide to 3 cycles 
of chemotherapy determined by histology. Patients also 
were treated with surgery and radiation. The histology 
determined systemic therapy included gemcitabine and 
dacarbazine for leiomyosarcoma, trabectedin for myxoid 
round cell liposarcoma, high dose ifosfamide for synovial 
sarcoma, ifosfamide and etoposide for malignant peripheral 
nerve sheath tumors, and gemcitabine with docetaxel for 
undifferentiated pleomorphic sarcoma. At a mean follow-
up of 12.3 months, the standard chemotherapy was superior 
to histology driven chemotherapy with a 46-month disease 
free survival of 62% versus 38% (P=0.006). In myxoid-
round cell liposarcoma, however, relapse free survival 
was similar with trabectedin and the standard epirubicin 
with ifosfamide. This study included 390 patients and was 
terminated early. We await further results (48).
Discussion
Subtypes of soft tissue sarcoma have been described for 
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over 150 years. Histologic subclassification of liposarcomas 
has been utilized for over 70 years. In the last 10–20 years, 
molecular and genetic characterization of these subtypes has 
evolved. Although few inclusive trials of systemic therapy 
have incorporated analysis of the response of histologic 
subtypes, several agents are being studied in specific subsets. 
Current clinical trials are underway in DDLPS of the 
agents cabazitaxel and plitidepsin. MLPSs is being evaluated 
for their response to sirolimus and cyclophosphamide in 
combination. In addition, based on the high response rate 
of MLPSs to chemotherapy, and the frequent presence of 
NY-ESO-1, T-cell directed cellular therapy targeting that 
antigen is the subject of a current clinical trial (Clinicaltrials.
gov 7/24/18).
In 2018, there is insufficient evidence to recommend 
selection of systemic therapy on the basis of the histologic 
subtype in most liposarcomas. An exception is MLPSs, 
which demonstrate particular sensitivity to trabectedin, 
though they generally have superior response to other agents 
as well. Analyses of histologic subtypes’ responsiveness 
to several newer agents, including Aldoxorubicin and 
Olaratumab, have not yet been published. A trial of 
histology driven selection of liposarcoma chemotherapy 
failed to achieve the desired improvement over a standard 
regimen. Extension of this concept to the study of histology 
driven subtypes of liposarcoma would be enlightening. 
Olaratumab and Aldoxorubicin have not yet been analyzed 
for their effectiveness in the varied subtypes of liposarcoma. 
In an uncommon disease, liposarcoma, the opportunity 
for study at the subtype level will require a collaborative 
effort among multiple institutions, and potentially across 
nations, to have sufficient cohort size for statistical 
evaluation. For now, the selection of systemic agents in the 
treatment of liposarcomas is not feasible due to the lack of 
robust data. The one exception is the myxoid/round cell 
liposarcoma subgroup. As a community of oncologists, 
we may choose to make recommendations regarding 
the inclusion of histologic subtype characterization in 
therapeutic trials, as a means of enabling subsequent meta-
analysis. 
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